ReviewCost effectiveness and resource allocation : C/E2025
Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review.
Mojtaba Jafari et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.